Evidence map›Paper›PMID 42392428›Full record

ReviewJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology2026

Immuno-positron emission tomography in cardiovascular disease: Advances, challenges, and opportunities.

Winston Lie, Sina Djafari Rouhani, Louise Clark, Sanjay Divakaran, Mohammad Rashidian

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Winston LieDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
Sina Djafari RouhaniDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
Louise ClarkDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.
Sanjay DivakaranHarvard Medical School, Boston, MA, USA; Center for Cardiovascular Imaging, Mass General Brigham, Boston, MA, USA. Electronic address: sdivakaran@bwh.harvard.edu.
Mohammad RashidianDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Radiology, Brigham and Women's Hospital, Boston, MA, USA. Electronic address: mohammad_rashidian@dfci.harvard.edu.

Funding

Training in Pharmacological SciencesT32GM132089 · NIGMS · HARVARD MEDICAL SCHOOL · PI DAVID E. GOLAN, Timothy J Mitchison · 2019 to 2026
$3.7M
Developing non-immunosuppressive immune-based therapeutics for targeted treatment of autoimmune diseasesR01AI165666 · NIAID · DANA-FARBER CANCER INST · PI Mohammad Rashidian, Erin wei · 2023 to 2026
$2.7M
Harvard Chemical Biology PhD ProgramT32GM139775 · NIGMS · HARVARD UNIVERSITY · PI Emily Patricia Balskus, PHILIP A COLE · 2022 to 2026
$2.6M
NIAID NIH HHS R01 AI165666NIGMS NIH HHS T32 GM132089NIGMS NIH HHS T32 GM139775
6 · The paper itself

Abstract

Cardiovascular diseases involve complex immune-associated biological processes that remain difficult to characterize using conventional imaging approaches. Although positron emission tomography (PET) has emerged as an important molecular imaging modality in cardiology, current metabolic tracers often lack sufficient specificity and may be limited by nonspecific myocardial uptake. Immuno-PET, which combines antibody-based targeting agents with the sensitivity and quantitative capability of PET, offers a promising strategy for noninvasive characterization of cardiovascular biology. In this review, we discuss emerging immuno-PET targets relevant to cardiovascular disease, including pan-leukocyte, lymphocyte-associated, myeloid/macrophage-associated, and vascular activation markers. We additionally review key technical and translational considerations for cardiovascular immuno-PET, including probe design, tissue penetration, blood clearance, radionuclide selection, and target-to-background limitations. Together, recent advances in antibody engineering, nanobody development, radiochemistry, and immune-target discovery are rapidly expanding the potential of immuno-PET for precision imaging of cardiovascular disease.

Indexed as

AntibodyCardiovascular diseasesImmuno-PETInflammationNanobody

Identifiers

PMID42392428
PMCPMC13401217

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.